BRIEF-Linvoseltamab In Combination With Carfilzomib Or Bortezomib Shows Promising Initial Results In Earlier Lines Of Treatment For Relapsed/Refractory Multiple Myeloma

Reuters
23 May
BRIEF-Linvoseltamab In Combination With Carfilzomib Or Bortezomib Shows Promising Initial Results In Earlier Lines Of Treatment For Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals Inc REGN.O:

  • LINVOSELTAMAB IN COMBINATION WITH CARFILZOMIB OR BORTEZOMIB SHOWS PROMISING INITIAL RESULTS IN EARLIER LINES OF TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • REGENERON PHARMACEUTICALS INC - 90% OBJECTIVE RESPONSE RATE IN LINVOSELTAMAB AND CARFILZOMIB COMBINATION

Source text: ID:nGNX9h5nCK

Further company coverage: REGN.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10